Riskpilot← Back to searchSign inGet full accessMonTa Biosciences ApS
APSActiveCVR 36697016Diplomvej 377, 1.Research and experimental development on natural sciences and engineering · NACE 7210Est. 20154 employeeswww.montabiosciences.com
Revenue 2024
DKK 1,5M
-27% vs 2023
EBITDA margin
-138.8%
-17% vs 2023
Equity ratio
-6.6%
Financial strength
Net profit 2024
DKK -3,9M
-20% vs 2023
| Revenue | DKK 1,5M | -27% |
| EBITDA | DKK -2,1M | -17% |
| Net profit | DKK -3,9M | -20% |
| Total assets | DKK 83,4M | +14% |
| Equity | DKK -5,5M | -244% |
| Employees | 4 | — |
Legal name
MonTa Biosciences ApS
CVR number
36697016
Legal form
Anpartsselskab
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
25. marts 2015
Share capital
DKK 2.629.981
Employees
4 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af Selskabets administrerende direktør og bestyrelsesformanden i forening eller af den samlede bestyrelse.
Company purpose
Selskabets formål er at drive forretning med udvikling og handel af målrettet lipidbaseret leveringsteknologi samt behandlinger af kræft, herunder projektet vedrørende udvikling af en stærk datapakke for TLR7 agonist 1V270 lipid formulering og dens immunoterapeutiske aktivitet til behandling af kræft med henblik på at opnå væsentlig kommerciel værdiskabelse og andre relaterede aktiviteter.
Address
Diplomvej 377, 1.
Email
simonjensen@montabiosciences.com
Website
www.montabiosciences.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2016 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | -79 | -25 | -178 | -7.101 | -13.310 | 2.130 | 1.757 | 2.025 | 1.480 |
| Staff expenses | -0 | -0 | -814 | -717 | -3.396 | -2.345 | -3.449 | -3.082 | -3.774 | -3.533 |
| EBITDA | 1 | -79 | -839 | -895 | -10.497 | -15.655 | -1.318 | -1.325 | -1.749 | -2.053 |
| Depreciation & amort. | -1 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | 0 | -79 | -839 | -895 | -10.497 | -15.655 | -1.318 | -1.325 | -1.749 | -2.053 |
| Net financials | -0 | 0 | 0 | 0 | -75 | -792 | -1.295 | -1.914 | -2.831 | -3.346 |
| Profit before tax | -0 | -79 | -839 | -895 | -10.572 | -16.447 | -2.613 | -3.239 | -4.580 | -5.400 |
| Tax | -0 | -17 | -185 | -135 | -1.984 | -3.155 | -4.019 | -1.800 | -1.302 | -1.479 |
| Net profit | -0 | -62 | -654 | -760 | -8.589 | -13.293 | 1.406 | -1.439 | -3.279 | -3.921 |
| Item | 2016 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 1 | 104 | 1.491 | 723 | 15.358 | 20.395 | 35.016 | 49.154 | 73.387 | 83.384 |
| Equity | 0 | 100 | 1.446 | 686 | 14.997 | 1.704 | 3.111 | 1.672 | -1.607 | -5.528 |
| Long-term debt | 0 | 0 | 0 | 0 | 86 | 15.686 | 29.924 | 43.827 | 70.663 | 84.055 |
| Short-term debt | 1 | 4 | 45 | 37 | 275 | 911 | 539 | 388 | 489 | 1.490 |
| Total debt | 1 | 4 | 45 | 37 | 361 | 16.598 | 30.463 | 44.216 | 71.152 | 85.545 |
EBITDA margin
-138.8%
This company
15.8%
Market median
-978% vs market
20162024
Equity ratio
-6.6%
This company
38.2%
Market median
-117% vs market
20162024
Return on equity
-392057200.0%
This company
18.4%
Market median
-2130745752% vs market
20162024
Net profit margin
-265.0%
This company
8.1%
Market median
-3372% vs market
20162024
Asset turnover
0.02×
This company
1.12×
Market median
-98% vs market
20162024
Debt / equity
16.08×
This company
0.62×
Market median
-2494% vs market
20162024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-07-01 – 2016-12-31
- Annual report 2016Filed via CVR / Virk · Period 2015-03-26 – 2016-06-30
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
LR Founder | Founder | 2015 | — | — |
TL Management | Management | 2015 | — | — |
SS Chief Executive Officer | Chief Executive Officer | 2015 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2019 | — | — | |
| Board of Directors | 2017 | — | — | |
| Chairman | 2017 | — | — | |
| Chairman | 2023 | — | — | |
| Board of Directors | 2025 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Consolidated Biosciences ApS | Company | 50.0% | 50.0% | 2022 |
JENSEN BIOCONSULT ApS | Company | 15.0% | 15.0% | 2022 |
TLA-HOLDING 2010 ApS | Company | 10.0% | 10.0% | 2022 |
| Individual | 5.0% | 5.0% | 2019 | |
Uddannelses- og Forskningsstyrelsen | Company | 10.0% | 10.0% | 2019 |
| Individual | 5.0% | 5.0% | 2016 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
TLA-HOLDING 2010 ApS
MonTa Biosciences ApS Board members of MonTa Biosciences ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Ladan Roursgaard | Founder | 0 companies |
| Thomas Lars Andresen | Management | 0 companies |
| Simon Skjøde Jensen | Chief Executive Officer | 0 companies |
| Sven Madsen | Board of Directors | 0 companies |
| Esper Boel | Board of Directors | 0 companies |
| Peter Birk Rasmussen | Chairman | 0 companies |
| Lone Schøtt Kunøe | Chairman | 0 companies |
| Søren Tulstrup | Board of Directors | 0 companies |